^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HER-2 exon 20 YVMA insertion

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
over1year
Performance of AmoyDx HER2 mutation detection kit and AmoyDx Pan Lung Cancer PCR Panel for detection of com-mon HER2 and/or EGFR mutations (ECP 2022)
In March 2019, AstraZeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo for trastuzumab deruxtecan (T-DXd; DS-8201)... Detection of rare mutations require sensitive and specific diagnostic assays. AmoyDx HER2 Mutation Detection Kit demonstrated robust performance in detecting representa-tive HER2 indel and single nucleotide variant mutations at low frequencies. The AmoyDx Pan Lung Cancer PCR assay showed similarly robust and sensitive detection of the common HER2 A775_G776insYVMA indel in addition to detecting clinically relevant EGFR mutations.
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • HER-2 V777L • HER-2 exon 20 YVMA insertion • HER-2 A775
|
AmoyDx® Pan Lung Cancer PCR Panel • AmoyDx® HER2 Mutation Detection Kit
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
almost2years
Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC (IASLC-WCLC 2022)
In 7 patients who received HER2-directed therapies, limited responses to afatinib (n=5), trastuzumab emtansine (n=3) and tucatinib (n=1) were observed and no responses were seen with immunotherapy monotherapy (n=2). The incidence of HER2-M+ is 3.1% in East Asian non-squamous NSCLC, with only 1/26 HER2ex20 overlapping with activating EGFR mutations. The clinical phenotype and genomic features of HER2ex20 tumours appear distinct from HER2other, the latter demonstrating higher TMB, co-occurring drivers and predominant non-ageing signature. The therapeutic implications of the genomic and clinical features of HER2-M+ warrant further investigation.)
Clinical • Tumor Mutational Burden • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden)
|
TP53 mutation • EGFR mutation • TMB-H • HER-2 mutation • EGFR wild-type • HER-2 exon 20 insertion • TMB-L • HER-2 A775_G776insYVMA • HER-2 L755P • HER-2 Y772_A775dup • HER-2 exon 20 mutation • HER-2 exon 20 YVMA insertion • HER-2 A775 • HER-2 exon 23 mutation
|
Gilotrif (afatinib) • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)